EpiPen® Shortage Updates
News Release – Health Minister announces access to a U.S.-approved epinephrine auto-injector
Interim Order Respecting Epinephrine Auto-Injectors
Explanatory Note: Epinephrine
Dear Healthcare Professional Letter
- During the shortage, and given the likelihood that quantities are expected to deplete across all pharmacies, pharmacists are encouraged to only process one EpiPen® per patient (where possible), effective immediately, to preserve supply in order to provide care to as many patients as possible until the product becomes available.
- EpiPen® products expire on the last day of the month indicated on the product packaging. For example, if the product is marked as expiring in August/2018, it remains valid (not expired) until August 31, 2018.
- Health Canada recommends that in this shortage situation if an individual is experiencing an anaphylactic reaction and has only an expired auto-injector immediately available, they should use the expired product and immediately contact 911. Regardless of whether the product is expired, as usual, a patient should get to the nearest hospital as soon as possible following the administration of the product.
- If pharmacies or patients do not have access to any form of EpiPen®, manual injection of epinephrine is an option. PAS worked together with medSask to create a supportive document on how to create an "epinephrine kit" and how to teach patients to administer a manual injection of epinephrine. Also, medSask created a video that can be used as a support for pharmacists and patients in the teaching process. PAS highly recommends that all pharmacists become familiar with kit contents and how to administer manual epinephrine.
- Pharmacists can reference the "Anaphylaxis Protocol" document on the PAS website, under the Influenza Immunization Program (and other injectables) area for information on dosing and other anaphylaxis protocol.
- There is a bulletin developed with input from Health Canada, Pfizer and pharmacy stakeholders which includes additional information and FAQs on the shortage.
If you have any questions or require additional support in managing an Epipen® shortage, please contact firstname.lastname@example.org.
medSask has created a resource document for pharmacists. This document is updated frequently by medSask and available on the link below.
Patient Information — Auvi-Q® (epinephrine injection) Auto-Injector For Allergic Emergencies (Anaphylaxis)
The 2019 PAS Membership and Malpractice Renewal is now open. PAS sent out an email last week to members on how they can renew their PAS membership.More
An Aging Population, Health care and the Role of Pharmacists in Saskatchewan with a National Comparison
The Pharmacy Association of Saskatchewan, in partnership with CPhA, commissions yearly public opinion surveys on public perceptions and attitudes towards pharmacists in Saskatchewan and across Canada.More
Update on EpiPen® Availability
There is a recent update from Pfizer Canada on EpiPen® and EpiPen Jr® auto-injectors.More
Joint CPhA/APhA Statement - Drug Importation Policy
The American Pharmacists Association (APhA) and the Canadian Pharmacists Association (CPhA) have issued a joint statement opposing U.S. federal legislation authorizing personal and commercial importation of prescription drugs from Canada.More